XORTX Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.4652
- Today's High:
- $0.5
- Open Price:
- $0.48
- 52W Low:
- $0.43
- 52W High:
- $2.29
- Prev. Close:
- $0.45
- Volume:
- 30598
Company Statistics
- Market Cap.:
- $6.48 million
- Book Value:
- 0.824
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -55%
- Return on Equity TTM:
- 78.15%
Company Profile
XORTX Therapeutics Inc had its IPO on 2018-11-28 under the ticker symbol XRTX.
The company operates in the Healthcare sector and Biotechnology industry. XORTX Therapeutics Inc has a staff strength of 0 employees.
Stock update
Shares of XORTX Therapeutics Inc opened at $0.48 at the start of the last trading session i.e. 2023-03-29.
The stocks traded within a range of $0.47 - $0.5, and closed at $0.48.
This is a +6.78% increase from the previous day's closing price.
A total volume of 30,598 shares were traded at the close of the day’s session.
In the last one week, shares of XORTX Therapeutics Inc have increased by +2.23%.
XORTX Therapeutics Inc's Key Ratios
XORTX Therapeutics Inc has a market cap of $6.48 million, indicating a price to book ratio of 1.4851 and a price to sales ratio of 0.
In the last 12-months XORTX Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-10007860. The EBITDA ratio measures XORTX Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, XORTX Therapeutics Inc’s operating margin was 0% while its return on assets stood at -55% with a return of equity of 78.15%.
In Q3, XORTX Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
XORTX Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0.9621
- Trailing PE
- 1.2503
- PEG
Its diluted EPS in the last 12-months stands at $0.36 per share while it has a forward price to earnings multiple of 0.9621 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into XORTX Therapeutics Inc’s profitability.
XORTX Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3551. Its price to sales ratio in the trailing 12-months stood at 0.
XORTX Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $14.96 million
- Total Liabilities
- $1.94 million
- Operating Cash Flow
- $-7265.00
- Capital Expenditure
- $580
- Dividend Payout Ratio
- 0%
XORTX Therapeutics Inc ended 2023 with $14.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.96 million while shareholder equity stood at $10.71 million.
XORTX Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $1.94 million in other current liabilities, 20009154.00 in common stock, $-16257380.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.16 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
XORTX Therapeutics Inc’s total current assets stands at $12.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $86546.00 compared to accounts payable of $1.33 million and inventory worth $0.
In 2023, XORTX Therapeutics Inc's operating cash flow was $-7265.00 while its capital expenditure stood at $580.
Comparatively, XORTX Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.48
- 52-Week High
- $2.29
- 52-Week Low
- $0.43
- Analyst Target Price
- $6.17
XORTX Therapeutics Inc stock is currently trading at $0.48 per share. It touched a 52-week high of $2.29 and a 52-week low of $2.29. Analysts tracking the stock have a 12-month average target price of $6.17.
Its 50-day moving average was $0.59 and 200-day moving average was $1 The short ratio stood at 0.95 indicating a short percent outstanding of 0%.
Around 314.4% of the company’s stock are held by insiders while 1397.3% are held by institutions.
Frequently Asked Questions About XORTX Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.